Amrita Krishnan, Md, Tells Us About The Results Of The Phase 1 Study Investigating Cc-93269 In Mm

Amrita Krishnan, MD, tells us about the results of the Phase 1 study investigating CC-93269 in MM

Amrita Krishnan, MD, tells us about the outcomes of the CARTITUDE-1 study presented at ASH 2019

Amrita Krishnan M.D., on Treatment Options for Multiple Myeloma | #ASCO21

Amrita Krishnan, M.D., Discusses a New Class of Myeloma Therapies | #ASCO21

Amrita Krishnan, MD, tells us about the Phase 3 Dreamm-3 study presented at ASH 2019

First-in-human study of talquetamab: a GPRC5D-CD3 bispecific antibody for R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc

Amrita Krishnan, M.D., at ASH 2019

MonumenTAL-1: updated data on talquetamab in R/R myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

ASCO 2019: Amrita Krishnan, M.D.

Amrita Krishnan, MD, discusses the future of isatuximab in the treatment of relapsed/refractory MM

Amrita Krishnan, MD, tells us about the outcomes of the ECOG trial in SMM

180 Updated Phase 1 Results of Teclistamab, a BCMA x CD3 Bispecific Antibody

Dr. Amrita Krishnan: Virtual NBC4 Broadcast | City of Hope Orange County

City of Hope Orange County

Amrita Krishnan, MD on the Best Myeloma Maintenance Approach After Transplant — IMW 2019

HealthTree Foundation for Multiple Myeloma

Meet Multiple Myeloma Specialist Amrita Krishnan, M.D. | City of Hope Orange County

City of Hope Orange County

Dr. Banerjee Describes Practice-Changing MM Data Presented at ASH 2024

Blood Cancers Today

MajesTEC-1: teclistamab for myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Amrita Krishnan, MD, elaborates on BCMA-directed strategies for multiple myeloma patients

Future applications of copper-64-labeled daratumumab PET/CT in MM

VJHemOnc – Video Journal of Hematology & HemOnc

Frontline Therapy’s Impact on Later Treatment in MM